Tairx, Inc.
Clinical trials sponsored by Tairx, Inc., explained in plain language.
-
New drug combo aims to shrink tough liver tumors
Disease control Recruiting nowThis study is testing whether adding a new oral drug called CVM-1118 to an existing immunotherapy (nivolumab) can better control advanced liver cancer that cannot be surgically removed. It is for about 95 adults whose cancer has progressed after standard treatments. The main goal…
Phase: PHASE2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New oral gel for tough cancers enters first human tests
Disease control Recruiting nowThis is the first study to test a new oral gel called TRX-920 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the highest safe dose, understand the drug's side effects, and see if it helps control the cancer. The gel…
Phase: PHASE1 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC